231 related articles for article (PubMed ID: 3017996)
1. Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport.
Hardwick JM; Shaw KE; Wills JW; Hunter E
J Cell Biol; 1986 Sep; 103(3):829-38. PubMed ID: 3017996
[TBL] [Abstract][Full Text] [Related]
2. Complete sequence of the Rous sarcoma virus env gene: identification of structural and functional regions of its product.
Hunter E; Hill E; Hardwick M; Bhown A; Schwartz DE; Tizard R
J Virol; 1983 Jun; 46(3):920-36. PubMed ID: 6304351
[TBL] [Abstract][Full Text] [Related]
3. Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products.
Wills JW; Srinivas RV; Hunter E
J Cell Biol; 1984 Dec; 99(6):2011-23. PubMed ID: 6094591
[TBL] [Abstract][Full Text] [Related]
4. A charged amino acid substitution within the transmembrane anchor of the Rous sarcoma virus envelope glycoprotein affects surface expression but not intracellular transport.
Davis GL; Hunter E
J Cell Biol; 1987 Sep; 105(3):1191-203. PubMed ID: 2821009
[TBL] [Abstract][Full Text] [Related]
5. Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein that block processing to gp85 and gp37.
Perez LG; Hunter E
J Virol; 1987 May; 61(5):1609-14. PubMed ID: 3033286
[TBL] [Abstract][Full Text] [Related]
6. Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions.
Wills JW; Hardwick JM; Shaw K; Hunter E
J Cell Biochem; 1983; 23(1-4):81-94. PubMed ID: 6327741
[TBL] [Abstract][Full Text] [Related]
7. Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions.
Perez LG; Davis GL; Hunter E
J Virol; 1987 Oct; 61(10):2981-8. PubMed ID: 3041017
[TBL] [Abstract][Full Text] [Related]
8. Distinct requirements for signal peptidase processing and function in the stable signal peptide subunit of the Junín virus envelope glycoprotein.
York J; Nunberg JH
Virology; 2007 Mar; 359(1):72-81. PubMed ID: 17045626
[TBL] [Abstract][Full Text] [Related]
9. Rous sarcoma virus mutant LA3382 is defective in virion glycoprotein assembly.
Hardwick JM; Hunter E
J Virol; 1981 Dec; 40(3):752-61. PubMed ID: 6172600
[TBL] [Abstract][Full Text] [Related]
10. Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage.
Dong JY; Dubay JW; Perez LG; Hunter E
J Virol; 1992 Feb; 66(2):865-74. PubMed ID: 1370559
[TBL] [Abstract][Full Text] [Related]
11. Transport of a lysosomally targeted Rous sarcoma virus envelope glycoprotein involves transient expression on the cell surface.
Johnston PB; Dong JY; Hunter E
Virology; 1995 Jan; 206(1):353-61. PubMed ID: 7831790
[TBL] [Abstract][Full Text] [Related]
12. Genetic analysis of the Rous sarcoma virus subgroup D env gene: mammal tropism correlates with temperature sensitivity of gp85.
Bova-Hill C; Olsen JC; Swanstrom R
J Virol; 1991 Apr; 65(4):2073-80. PubMed ID: 1848317
[TBL] [Abstract][Full Text] [Related]
13. The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160.
Fenouillet E; Jones IM
J Gen Virol; 1995 Jun; 76 ( Pt 6)():1509-14. PubMed ID: 7782780
[TBL] [Abstract][Full Text] [Related]
14. Prototype foamy virus envelope glycoprotein leader peptide processing is mediated by a furin-like cellular protease, but cleavage is not essential for viral infectivity.
Duda A; Stange A; Lüftenegger D; Stanke N; Westphal D; Pietschmann T; Eastman SW; Linial ML; Rethwilm A; Lindemann D
J Virol; 2004 Dec; 78(24):13865-70. PubMed ID: 15564494
[TBL] [Abstract][Full Text] [Related]
15. Palmitoylation of the Rous sarcoma virus transmembrane glycoprotein is required for protein stability and virus infectivity.
Ochsenbauer-Jambor C; Miller DC; Roberts CR; Rhee SS; Hunter E
J Virol; 2001 Dec; 75(23):11544-54. PubMed ID: 11689636
[TBL] [Abstract][Full Text] [Related]
16. Expression of the TM protein of Rous sarcoma virus in the absence of SU shows that this domain is capable of oligomerization and intracellular transport.
Einfeld DA; Hunter E
J Virol; 1994 Apr; 68(4):2513-20. PubMed ID: 8139033
[TBL] [Abstract][Full Text] [Related]
17. Parallel effects of signal peptide hydrophobic core modifications on co-translational translocation and post-translational cleavage by purified signal peptidase.
Cioffi JA; Allen KL; Lively MO; Kemper B
J Biol Chem; 1989 Sep; 264(25):15052-8. PubMed ID: 2549048
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation.
Dubay JW; Dubay SR; Shin HJ; Hunter E
J Virol; 1995 Aug; 69(8):4675-82. PubMed ID: 7609032
[TBL] [Abstract][Full Text] [Related]
19. A single glycosylation site within the receptor-binding domain of the avian sarcoma/leukosis virus glycoprotein is critical for receptor binding.
Delos SE; Burdick MJ; White JM
Virology; 2002 Mar; 294(2):354-63. PubMed ID: 12009877
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of the oligomer assembly domain in the transmembrane subunit of the Rous sarcoma virus glycoprotein.
Einfeld DA; Hunter E
J Virol; 1997 Mar; 71(3):2383-9. PubMed ID: 9032375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
